期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 10, 期 3, 页码 405-419出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.883921
关键词
active immunotherapy; Alzheimer's disease; cognitive disorders; dementia; gantenerumab; monoclonal antibody; passive immunotherapy; solanezumab
类别
资金
- Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN) [2009E4RM4Z]
Both active and passive anti--amyloid (A) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated clearance of brain A deposits. Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A, were disappointing. Also solanezumab, directed at the mid-region of A, failed in two Phase III trials in mild-to-moderate AD. Another Phase III trial with solanezumab is ongoing in mildly affected AD patients based on encouraging results in this subgroup. Second-generation active A vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-A immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing. These new anti-A immunotherapies are being tested in prodromal AD, in presymptomatic subjects with AD-related mutations, or in asymptomatic subjects at risk of developing AD. These primary and secondary prevention trials will definitely test the A cascade hypothesis of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据